The five biggest pharmaceutical companies by market cap are Johnson & Johnson, Roche Holding, Pfizer, Novo Nordisk and Eli Lilly.
The biggest pharmaceutical companies in the world are responsible for developing and manufacturing the vast majority of prescription drugs, giving them a key role in the life science industry.
The pharmaceutical sector is responsible for the discovery, development and manufacturing of drugs and medicine. Today’s pharma companies are developing innovative treatments in areas like immuno-oncology and neurology, as well as novel options for a range of rare diseases.
With the pharmaceutical sector projected to reach a staggering US$1 trillion in total revenue by 2026, the need for the industry is great. Opportunities for investment are also sizeable, but what's the best place to start? Those who want exposure to the pharma market may want to begin by looking at the major players in the space.
With that in mind, here are the five biggest drug companies by market cap size. Data for this article was compiled using Investing.com’s stock screener on March 9, 2022, and stocks are listed from largest to smallest.
1. Johnson & Johnson (NYSE:JNJ)
Market cap: US$445.77 billion
Starting off this list of the biggest pharmaceutical companies is Johnson & Johnson, a holding company focused on the overarching life science field. Life science companies often specify their focus, but thanks to its massive scale, Johnson & Johnson covers many areas through its subsidiaries.
In terms of pharmaceuticals, Johnson & Johnson’s focus is on six therapeutic areas: cardiovascular disease and metabolism, infectious diseases and vaccines, neuroscience, oncology, immunology and pulmonary hypertension.
2. Roche Holding (OTCQX:RHHBY)
Market cap: US$328.57 billion
Roche Holding is one of the largest biotech companies. Its reach expands into oncology, immunology, ophthalmology and diseases related to the central nervous system. The company has more than 90,000 employees spanning 100 countries around the globe, and Roche boasts that it spends approximately 9 billion Swiss francs on research and development each year.
The pharmaceutical division of its business is focused on developing medicines for areas with unmet needs, such as oncology, immunology, opthalmology, infectious diseases and neuroscience.
3. Pfizer (NYSE:PFE)
Market cap: US$276.28 billion
Another giant in the medical world, Pfizer is active in the development of multiple healthcare products. Its areas of focus include medical disciplines such as immunology, oncology, cardiology, endocrinology and neurology.
The company operates its commercial divisions under two segments: Pfizer Innovative Health and Pfizer Essential Health. The former focuses on products for consumer healthcare, along with medicines and vaccines that directly improve patient lives, while the latter is centered on therapeutic areas such as internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare.
4. Novo Nordisk (NYSE:NVO)
Market cap: US$238.03 billion
Founded in 1923, Denmark-based Novo Nordisk has honed its efforts on diabetes and other serious chronic diseases, such as cardiovascular diseases, obesity and rare blood and endocrine disorders. The company’s operations span 80 countries and it markets products in around 170 countries.
In an effort to compete with rival companies in the insulin market, Novo Nordisk has launched smart insulin self-injection pens in the UK. The app-supported NovoPen 6 and NovoPen Echo Plus provide diabetes patients with a less invasive way to monitor and record dosing information. The use of digital technologies in healthcare is a growing trend as pharma companies seek to improve the safety and efficacy of medical treatments.
5. Eli Lilly (NYSE:LLY)
Market cap: US$237.84 billion
Founded in 1876, Eli Lilly and Company develops products for human and animal health. Its human pharma products include therapies for endocrinology, neuroscience, oncology, immunology and cardiovascular disorders.
Eli Lilly has research and development facilities and manufacturing plans in eight countries and has done clinical research in over 50 countries. In 2022 and beyond, analysts in the life science space expect to see more developments in Alzheimer’s treatments out of this pharma giant.
This is an updated version of an article originally published by the Investing News Network in 2016.
Don’t forget to follow @INN_LifeScience for real-time updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
- 10 Top Pharmaceutical Stocks by Revenue | INN ›
- 5 Biggest Canadian Pharma Stocks | INN ›
- Why Consider Investing in Pharmaceutical Stocks? | INN ›
- Pharmaceutical Industry Overview: Top Regions | INN ›
- Top Canadian Biotech Stocks | INN ›
- Top Canadian Pharma Stocks | INN ›
- Top Canadian Pharma Stocks | INN ›